ARTICLE | Clinical News
Chimerix jumps on Phase III trial start for CMX001
September 10, 2013 12:28 AM UTC
Chimerix Inc. (NASDAQ:CMRX) gained $2.73 (17%) to $19.07 on Monday after starting the Phase III SUPPRESS trial of brincidofovir ( CMX001) to prevent cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) patients. Data are expected in 2015. Chimerix also is developing CMX001 to prevent smallpox infection under a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA). The compound is an oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the antiviral agent cidofovir diphosphate. ...